Extending Visit Intervals for Clinically Stable Patients on Antiretroviral Therapy: Multicohort Analysis of HIV Programs in Southern Africa.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
01 08 2019
Historique:
entrez: 27 6 2019
pubmed: 27 6 2019
medline: 25 2 2020
Statut: ppublish

Résumé

The World Health Organization recommends differentiated antiretroviral therapy (ART) delivery with longer visit intervals for clinically stable patients. We examined time trends in visit frequency and associations between criteria for clinical stability and visit frequency in ART programs in Southern Africa. We included adults on ART from 4 programs with viral-load monitoring, 2 programs with CD4 monitoring, and 4 programs with clinical monitoring of ART. We classified patients as clinically stable based on virological (viral load <1000 copies/mL), immunological (CD4 >200 cells/µL), or clinical (no current tuberculosis) criteria. We used Poisson regression and survival models to examine associations between criteria for clinical stability and the rate of clinic visits. We included 180,837 patients. There were trends toward fewer visits in more recent years and with longer ART duration. In all ART programs, clinically stable patients were seen less frequently than patients receiving failing ART, but the strength of the association varied. Adjusted incidence rate ratios comparing visit rates for stable patients with patients on failing ART were 0.82 (95% confidence interval: 0.73 to 0.90) for patients classified based on the virological criterion, 0.81 (0.69 to 0.93) for patients classified based on the clinical criterion, and 0.90 (0.85 to 0.96) for patients classified based on the immunological criterion for stability. Differences in visit rates between stable patients and patients failing ART were variable and modest overall. Larger differences were seen in programs using virological criteria for clinical stability than in programs using immunological criteria. Greater access to routine viral-load monitoring may increase scale-up of differentiated ART delivery.

Sections du résumé

BACKGROUND
The World Health Organization recommends differentiated antiretroviral therapy (ART) delivery with longer visit intervals for clinically stable patients. We examined time trends in visit frequency and associations between criteria for clinical stability and visit frequency in ART programs in Southern Africa.
METHODS
We included adults on ART from 4 programs with viral-load monitoring, 2 programs with CD4 monitoring, and 4 programs with clinical monitoring of ART. We classified patients as clinically stable based on virological (viral load <1000 copies/mL), immunological (CD4 >200 cells/µL), or clinical (no current tuberculosis) criteria. We used Poisson regression and survival models to examine associations between criteria for clinical stability and the rate of clinic visits.
RESULTS
We included 180,837 patients. There were trends toward fewer visits in more recent years and with longer ART duration. In all ART programs, clinically stable patients were seen less frequently than patients receiving failing ART, but the strength of the association varied. Adjusted incidence rate ratios comparing visit rates for stable patients with patients on failing ART were 0.82 (95% confidence interval: 0.73 to 0.90) for patients classified based on the virological criterion, 0.81 (0.69 to 0.93) for patients classified based on the clinical criterion, and 0.90 (0.85 to 0.96) for patients classified based on the immunological criterion for stability.
CONCLUSION
Differences in visit rates between stable patients and patients failing ART were variable and modest overall. Larger differences were seen in programs using virological criteria for clinical stability than in programs using immunological criteria. Greater access to routine viral-load monitoring may increase scale-up of differentiated ART delivery.

Identifiants

pubmed: 31242142
doi: 10.1097/QAI.0000000000002060
pii: 00126334-201908010-00012
pmc: PMC6597180
mid: NIHMS1525564
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

439-447

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States

Références

J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29130601
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):45-51
pubmed: 24872139
Trop Med Int Health. 2016 Sep;21(9):1124-30
pubmed: 27371814
J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e16-23
pubmed: 26473798
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S124-S127
pubmed: 29994834
Int J Epidemiol. 2012 Oct;41(5):1256-64
pubmed: 21593078
Stat Med. 2002 Aug 15;21(15):2175-97
pubmed: 12210632
J Int AIDS Soc. 2018 Mar;21(3):
pubmed: 29537628
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21648
pubmed: 28770597
Lancet HIV. 2015 Jul;2(7):e271-8
pubmed: 26423252
BMC Health Serv Res. 2014 Aug 19;14:352
pubmed: 25138583
PLoS One. 2018 Jun 11;13(6):e0198686
pubmed: 29889862
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
Trop Med Int Health. 2015 Apr;20(4):430-47
pubmed: 25583302
Clin Infect Dis. 2018 Jan 6;66(2):237-243
pubmed: 29020295
Clin Infect Dis. 2018 Sep 28;67(8):1269-1277
pubmed: 29635466
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21647
pubmed: 28770599
Nature. 2015 Dec 3;528(7580):S68-76
pubmed: 26633768
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
Clin Infect Dis. 2018 Mar 5;66(6):893-903
pubmed: 29373672
AIDS. 2014 Mar;28 Suppl 2:S161-9
pubmed: 24849476

Auteurs

Andreas D Haas (AD)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Leigh F Johnson (LF)

Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Anna Grimsrud (A)

International AIDS Society, Cape Town, South Africa.

Nathan Ford (N)

Department of HIV/AIDS World Health Organization, Geneva, Switzerland.

Catarina Mugglin (C)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Matthew P Fox (MP)

Department of Internal Medicine, Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Global Health, Boston University School of Public Health, Boston, MA.

Jonathan Euvrard (J)

Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Monique van Lettow (M)

Dignitas International, Zomba, Malawi.
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Hans Prozesky (H)

Division of Infectious Diseases, Department of Medicine, Tygerberg Academic Hospital, University of Stellenbosch, Cape Town, South Africa.

Izukanji Sikazwe (I)

Centre for Infectious Diseases Research in Zambia, Lusaka, Zambia.

Cleophas Chimbetete (C)

Newlands Clinic, Harare, Zimbabwe.

Michael Hobbins (M)

SolidarMed, Lucerne, Switzerland.

Cordelia Kunzekwenyika (C)

SolidarMed, Masvingo, Zimbabwe.

Matthias Egger (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH